Omar M. Agnaf-El
Doha, DA, Qatar
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Auto-immunoproteomics analysis of COVID-19 ICU patients revealed increased levels of autoantibodies related to the male reproductive system.
Journal: Frontiers in physiology
Published: April 11, 2023
The immune system in Parkinson's disease: From biology to diagnosis and therapeutic targets.
Journal: Neurobiology of disease
Published: January 10, 2023
Immune-related biomarkers for Parkinson's disease.
Journal: Neurobiology of disease
Published: February 09, 2022
Prion-like α-synuclein pathology in the brain of infants with Krabbe disease.
Journal: Brain : a journal of neurology
Published: October 20, 2021
Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein.
Journal: Frontiers in aging neuroscience
Published: December 07, 2020
CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
Journal: International journal of molecular sciences
Published: October 22, 2020
CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: July 19, 2019
Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration.
Journal: Brain : a journal of neurology
Published: April 30, 2018
Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid.
Journal: Bioanalysis
Published: May 16, 2017
A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
Journal: PloS one
Published: November 23, 2015
Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
Journal: Expert opinion on therapeutic targets
Published: July 03, 2015
Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit.
Journal: Biological psychiatry
Published: May 05, 2015
Last Updated: 09/26/2026